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Abstract The biologist Lewis Thomas once wrote: “my
mitochondria comprise a very large proportion of me. I
cannot do the calculation, but I suppose there is almost as
much of them in sheer dry bulk as there is the rest of me”.
As humans, or indeed as any mammal, bird, or insect, we
contain a specific molecular makeup that is driven by vast
numbers of these miniscule powerhouses residing in most
of our cells (mature red blood cells notwithstanding),
quietly replicating, living independent lives and containing
their own DNA. Everything we do, from running a
marathon to breathing, is driven by these small batteries,
and yet there is evidence that these molecular energy
sources were originally bacteria, possibly parasitic, incorpo-
rated into our cells through symbiosis. Dysfunctions in these
organelles can lead to debilitating, and sometimes fatal,
diseasesofalmostall the bodies’ major organs. Mitochondrial
dysfunction has been implicated in a wide variety of human
disorders either as a primary cause or as a secondary
consequence. To better understand the role of mitochondrial
dysfunction in human disease, a multitude of pharmacolog-
ically induced and genetically manipulated animal models
have been developed showing to a greater or lesser extent the
clinical symptoms observed in patients with known and
unknown causes of the disease. This review will focus on
diseases of the brain and spinal cord in which mitochondrial
dysfunction has been proven or is suspected and on animal
models that are currently used to study the etiology,
pathogenesis and treatment of these diseases.
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Introduction
It has long been known that the energy source for all
eukaryotic cells is the organelle called the mitochondrion.
These organelles, thought to be incorporated as bacteria
into our cells at some point in our evolution, contain their
own DNA, inherited from our mothers, and replicate
through cloning, fission and fusion. There has been some
debate as to whether or not the original symbiosis between
mitochondrion and cell was more beneficial to the
mitochondria, or more damaging to the cell in which it
resides (Searcy 2003), but it is generally agreed that cells
receiving their energy from mitochondria are infinitely
more successful than bacterial cells, which generate their
energy without them. Mitochondria serve multiple purposes
in our bodies, among which include the modulation of both
cell proliferation and programmed cell death (Carreras et al.
2007). One of the most important functions of the
mitochondria is to convert energy from macronutrients
(fatty acids, carbohydrates and amino acids) to ATP, through
the oxidation of the macronutrients, reducing oxygen to
water, and phosphorylating adenosine diphosphate (ADP)
to ATP (Schiff et al. 2011)(For a more in depth description
of oxidative phosphorylation, please see Boveris and
Navarro 2008). The mitochondrial respiratory chain is
found in the mitochondrial inner membrane, and consists
of four complexes. Reduced equivalents from sugar-derived
organic acids, from amino acids, or from fatty acids enter
the chain via dehydrogenases (complexes I and II), and are
then subsequently transferred to complexes III and IV. With
each transfer, electrons release energy into the intermem-
brane space, creating a proton gradient. The flow of protons
back through complex V is responsible for the generation of
ATP; complex Vis also responsible for the release of energy
stored in the proton gradient by facilitating proton flow into
the mitochondrial matrix (Clay et al. 2010). However,
defects in mitochondrial function, especially in respiration,
can lead to debilitating, possibly fatal, abnormalities. For
example, mitochondrial dysfunction has been linked to
such neurodegenerative and neurological diseases as
Parkinson’s, Alzheimer’s and Huntington’s, as well as
amyotrophic lateral sclerosis (ALS), schizophrenia and
depression, and can also result in growth retardation,
optic atrophy, hypertrophic cardiomyopathy, and metabolic
disorders (Levine et al. 2004; Ben-Shachar 2009;C l a ye ta l .
2010). This review will examine the health implications of
mitochondrial dysfunctions, specifically focusing on brain
aberrations, how these abnormalities have been modeled in
vivo and how symptoms may be improved through either
pharmacological or nutritional interventions. Since there is an
excess of information about numerous knockout, knock-in,
transgenic and induction animal models, only those that have
been examined in behavioral paradigms, with or without
pharmaceutical or nutraceutical interventions, will be
discussed here.
Mitochondrial dysfunction: the human brain
and spinal cord
Disruptions in mitochondrial function can have severe
consequences, not the least of which is neurodegeneration
in the brain. The production of damaging reactive oxygen
species (ROS) by dysfunctional mitochondria may lead to
increases in oxidative stress and subsequent neuronal death.
The brain is extremely susceptible to oxidative stress,
because it consumes significant amounts of oxygen, but has
fewer defenses against free radicals (Weinstock and Shoham
2003). Further explanations as to the brain’ss e n s i t i v i t yt o
ROS include the fact that the brain is rich in polyunsaturated
fatty acids (PUFAs), which are highly susceptible to ROS
damage (Cui et al. 2004). Further, the release of excitatory
neurotransmitters, such as glutamate, begins a chain of
reactions in the postsynaptic neurons, which also result in the
formation of ROS (Cui et al. 2004). However, the underlying
mitochondrial cause for neurodegenerative diseases does not
only include the production of ROS. Other factors, such as
altered calcium flux and energy generation dysfunctions can
make significant contributions. For example, events such as
mitochondrial outer membrane permeabilization (MOMP)
194 J Inherit Metab Dis (2012) 35:193–210can lead to mitochondrial respiratory dysfunctions, resulting
in the release of such proteins as Apoptosis Inducing Factor
(AiF) and cytochrome c. Since neurons in the brain are
highly sensitive to changes in mitochondrial respiration,
changes in MOMP may ultimately lead to neurodegeneration
(Green and Kroemer 2004). Furthermore, mitochondria have
a large capacity for calcium uptake and are integral for
calcium storage in cells. Calcium flux is regulated by the
mitochondrial inner membrane potential; disturbances in
calcium flux may result in increased calcium uptake by the
mitochondria, resulting in apoptosis and neuronal death
(Andrews et al. 2005).
There is increasing evidence that these disruptions in
mitochondrial function and increased oxidative stress may
play a role in the development of neurodegenerative
diseases such as Parkinson’s (PD), Alzheimer’s( A D ) ,
Huntington’s (HD), and ALS (Lin and Beal 2006), as
well as the development of depression, anxiety, and
schizophrenia (Scaglia 2010)(Table 1) .A g i n ga l s op l a y s
a significant role in the development of neurodegenerative
diseases, as mitochondria are thought to speed the process
of senescence through the accumulation of mitochondrial
DNA (mtDNA) mutations, which correlate with declining
mitochondrial function and subsequent neurodegeneration
(Lin and Beal 2006). For a more in depth overview of
mitochondrial dysfunction, oxidative stress and the roles
they play in neurodegenerative diseases, please see Lin
and Beal 2006.
Whatever the cause, the fact remains that disruptions in
mitochondrial functioning have significant effects on the
development of neurodegenerative diseases. The first
evidence for this was found in the unlikely source of drug
abusers: those who were accidentally exposed to the drug
1-methyl 4-phenyl 1,2,3,6-tetrahydropyridine (MPTP), the
metabolite of which (MPP) is extremely neurotoxic (and
also happens to be a complex I inhibitor), developed PD
(Langston et al. 1983; Choi et al. 2008; Schapira 2010).
Parkinson’s disease
Most often, neurons in the motor centers of the brain, such
as the cerebellum and striatum, have been found to be
decreased in PD patients, along with a dramatic decrease of
dopamine neurons in the substantia nigra pars compactica
(SNpc) and the generation of proteinaceous inclusions
known as Lewy bodies, also in dopamine (DA) neurons
(Tansey and Goldberg 2010). However, patients presenting
with PD often show multiple symptoms and brain histology
points to several causes, not just the depletion of dopami-
nergic neurons. Decreases in Purkinje cell numbers in the
cerebellum have also been observed in the brains of
patients with neurodegenerative diseases, correlating with
a loss of motor skills (Mounsey and Teismann 2010).
Symptoms of PD include tremor, rigidity, bradykinesia
(slowed movement), and postural instability (Xiong et al.
2009). The cause of PD is at this point still relatively
unknown as most cases have no genetic links, but it is
thought that dysfunctions in mitochondrial respiration,
especially in complex I, result in increased ROS production,
oxidative stress and dopaminergic neuronal degeneration,
all of which are associated with the development of PD
( d eM o u r ae ta l .2010).
Huntington’s disease
The neurodegenerative basis for HD is characterized by
multiple “CAG” replications in the huntingtin gene. Those
affected begin to experience decreased motor function and
eventually descend into the gloom of severe cognitive
impairment (Novak and Tibrizi 2010). The more CAG
copies present, the faster the disease progression, and there
is no cure. The hallmarks of HD include widespread
nuclear inclusions in the brain and significant decreases in
medium sized spiny neurons (MSSN) in the striatum
(Levine et al. 2004). However, even though there is
evidence that mitochondrial dysfunction may play a
significant role in the development of HD, the precise role
played by the mitochondria in the disease pathology is
unknown (Oliveira 2010). Post mortem examination of
brains of advanced HD sufferers does show reduced in vitro
activity of mitochondrial complexes II, III and IV (Browne
et al. 1997). Aconitase activity has also been shown to be
significantly decreased in HD sufferers (as well as in the
striatum of R6/2 knock in mice, an in vivo model for HD),
further underlining the importance of mitochondrial
dysfunction in the development of this disease, since
aconitase is particularly vulnerable to free radicals (Chen
2011). However, those with pre-symptomatic or early
cases of HD did not show mitochondrial respiration
deficiencies, and striatal oxygen metabolism appeared to
be normal (Oliveira 2010).
Alzheimer’s disease
The hallmarks of Alzheimer’s disease include severe
decreases in memory, accompanied by deterioration of
intellectual function, personality changes, and inability for
self care (Masliah et al. 1994). In the brain, the diseases
manifests in the form of neurofibrillary tangles comprised
mainly of hyperphosphorylated tau proteins and extracellular
senile plaques composed of β-amyloid and mostly found on
cholinergic neurons supplying the hippocampus (Dragicevic
et al. 2010). Disruptions in mitochondrial respiration have
been thought to play a role in the development of the
disease, as rats injected with the drug sodium azide, a
selective complex IV inhibitor, show cognitive deficits
J Inherit Metab Dis (2012) 35:193–210 195T
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196 J Inherit Metab Dis (2012) 35:193–210similar to those suffering AD (Bennett et al. 1996). Complex
IV plays an important role in energy metabolism and the
production of adenosine tri-phosphate (ATP) (Hirai et al.
2001; Smeitink et al. 2001).
Amyotrophic lateral sclerosis
Amyotrophic lateral sclerosis (ALS), also known as motor
neuron disease and Lou Gehrig’s disease, has no known
cause outside of the few familial cases resulting from
mutations in the superoxide dismutase 1 (SOD1) gene.
SOD1, a soluble cytoplasmic and mitochondrial intermem-
brane space protein, is responsible for the conversion of
superoxide into oxygen and hydrogen peroxide, protecting
the cell from superoxide toxicity. ALS is characterized by
cognitive and motor deficits, with a loss of motor neurons
in the cortex, brain stem and spinal cord, as well as
neurofilament aggregates in the proximal axons of motor
neurons. The hallmarks of ALS, known as Bunina bodies,
are eosinophilic bodies found in the soma of anterior horn
cells (Goodall and Morrison 2006). More recently, it has
been discovered that mutations in TARDBP, the gene
encoding the transactivation response DNA-binding protein
TDP-43, results in an ALS phenotype in transgenic mice
(TDP-43PrP). This protein is the main component of
ubiquinated aggregates in the brain and causes the loss of
motor neurons, resulting in ALS symptoms and ultimately,
premature death (Xu et al. 2010; Shan et al. 2010). Shan et
al. (2010) also point out that mutations in the FUS/TLS
gene, encoding for another RNA-binding protein, is linked
to ALS, suggesting that alterations in RNA metabolism or
processing may also contribute to neurodegeneration. There
is no effective treatment for ALS to date, and most of those
diagnosed will succumb to the disease within 3 to 5 years
after diagnosis (Fornai et al. 2008).
Neuropsychiatric diseases
Mitochondrial dysfunction has also been implicated in the
development of several neuropsychiatric diseases such as
depression, anxiety and schizophrenia. There is evidence
that dysfunctions in mitochondrial respiration have severe
consequences for monoamine levels in the brain, resulting
in decreases in serotonin (5-hydroxytryptamine, or 5-HT),
dopamine, noradrenaline, and gamma aminobuteric acid
(GABA)(Gardner and Boles 2010), all of which are
monoamines associated with depressive, schizophrenic
and anxious behaviors. For example, ties have been found
between mitochondrial dysfunction and the development of
schizophrenia: microscopic analysis of autopsy specimens
show mitochondrial malformations and reduced density in
the anterior limbic cortex and the caudate putamen nucleus,
both areas highly associated with the development of
schizophrenia (Ben-Shachar 2009). Mitochondrial dysfunc-
tion has also been linked to decreases in brain-derived
neurotrophic factor (BDNF), decreases in hippocampal
neurons and disruption of the hypothalamus-pituitary-
adrenal (HPA) axis, all of which has been linked to the
development of depressive and anxious symptoms (Clay
et al. 2010;W ue ta l .2010).
The scope and severity of the above named disorders
makes it clear that much work needs to be done examining
the causes and treatments for neurodegenerative and
psychiatric disorders, perhaps with a stronger focus on
mitochondrial dysfunction. One of the most often used and
valid ways to accomplish this goal is through the use of
animal models. Currently, several animal models exist that
specifically replicate certain aspects of many of the
aforementioned diseases. The use of these models is key
to the development of new and improved treatments, and
may even lead to more clues as to the connections between
mitochondrial dysfunction and neurodegenerative diseases.
In vivo modeling of mitochondrial dysfunction
While several breakthroughs have been made as to
understanding the reactions of isolated mitochondria to
various stimuli under in vitro conditions, it is important to
understand the working mechanisms of these organelles in
vivo. Animal models are extremely useful, and even
necessary, when observing the effects of mitochondrial
respiration and its effects on brain function (Table 2).
Indeed, without the use of these animal models, finding
treatments for mitochondrial diseases would be next to
impossible.
Mouse models for mitochondrial complex I deficiencies
Ndufs4 knockout mouse
With the advent of genetic engineering, it has become
possible to generate specific animal models for diseases.
Along these lines, the Ndufs4 mouse knockout was
generated for the purpose of examining mitochondrial
complex I disorders. In short, inactivation of the Ndufs4
gene directly effects the encoding of mitochondrial complex I
(Kruse et al. 2008), resulting in a phenotype that includes
many of the symptoms seen in humans suffering the same
affliction: low birth weight, followed by subsequent failure
to thrive, partial to total blindness, and impairments in motor
function; these mice often die about seven weeks after
birth. Knockout mice also exhibit abnormal mitochondrial
morphology in the soleus muscle, characterized by swollen
mitochondria containing condensed cristae (Quintana et al.
2010; Kruse et al. 2008). Puzzlingly, these mice exhibit
J Inherit Metab Dis (2012) 35:193–210 197normal muscular oxygen consumption and ATP levels and
have normal fasting blood glucose levels (Kruse et al. 2008).
Therefore, it must be assumed that the cause of early death in
these animals is not directly dependent on mitochondrial
respiration abnormalities, but perhaps is more connected to
the sensitivity of the brain to oxidative stress. Since the brain
is less adept at protecting itself from free radicals, it may be
that these animals are more susceptible to neurological ROS
damage. Indeed, these animals show neurodegeneration from
an early age (approximately 5 weeks), as seen from their
decreased performance in the rotarod and rope grip
paradigms, as well as cognitive dysfunctions. Knockout
animals show decreases in Purkinje cells in the cerebellum,
and neuronal damage in the striatum and hippocampus
(Kruse et al. 2008). The fact that these animals have
significantly decreased body temperatures (up to 4°C less
than wild types) and have significantly increased responses
in a startle paradigm may also indicate compromises in
their brain monoamine system, particularly serotonin. It
may be that mitochondrial dysfunctions in these animals
also leads to disruptions in their homeostasis, resulting in
decreased body temperature, altered appetite, and disrupted
circadian rhythms.
Interestingly, others examining in vivo Ndufs4 mutations
have found an embryonically lethal phenotype in knockout
animals, while heterozygotes show more of the behavioral
characteristics typically found in the knockouts in other
labs (Ingraham et al. 2009). However, this group, instead of
knocking out the entire NDUFS4 protein, only eliminated
the last 10–15 amino acids, which may account for the
lethal phenotype of their knockout animals.
The harlequin mouse
This particular knockout mouse was also generated to
study the effects of mitochondrial dysfunction on disease
progression (Ishimura et al. 2008). The mutation is a
result of a proviral insertion in the X-linked gene encoding
the mitochondrial protein Apoptosis Inducing Factor (AiF)
(Benit et al. 2008). This causes a 20% decrease of AiF
compared to wild types, and results in characteristics that
are similar to the Ndufs4 mouse, but show a generally
more stable phenotype, allowing it to live significantly
longer than Ndufs4s. These animals also show fur loss
around about three months of age, severe cerebellar ataxia,
optic tract dysfunctions, and have an increased risk of
hypertrophic cardiomyopathy (Benit et al. 2008). Similarly
to the Ndufs4 knockout, these animals show severe deficits
on the rotarod test for motor coordination. Since the
mutation is X-linked, the majority of animals showing
abnormalities are male, and then only about 50% show
growth abnormalities. However, almost all animals, males
and females, are ataxic at about 3 months; 90% of the
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198 J Inherit Metab Dis (2012) 35:193–210heterozygotes have gait ataxia at this age (Benit et al.
2008). Brain pathology at six months of age reveals that
complex I activity is significantly decreased in the
cerebellum, thalamus and cortical enriched fraction, as
well as in the optic nerves and retinas, compared to wild
types. However, complex I activity is normal in the heart,
liver and testes, and decreased by 30% in skeletal muscle
(Benit et al. 2008). It is interesting that two different
animal models, both examining the effects of complex I
function, should differ from each other so drastically in
life expectancy and pathology. The AiF mutation has been
hypothesized to result in an independent pathogenic
mechanism, responsible for destabilization of the inner
mitochondrial membrane. This destabilization leaves the
respiratory chain and its functions open to damage,
leading to the deficiencies in complex I function (Ghezzi
et al. 2010). However, the exact mechanism behind the
effects of AiF on the mitochondrial respiratory chain in
both humans and the Harlequin mouse remains unknown.
Models for Parkinson’s disease
The Mitopark mouse
The MitoPark mouse is a transgenic model for Parkinson’s
disease, in which the mitochondrial transcription factor
Tfam is selectively removed from midbrain dopamine
neurons. Neurons lacking Tfam develop severe mitochon-
drial respiratory chain deficiencies and ultimately undergo
cell death (Galter et al. 2010) resulting in a slow
progression of PD symptoms as seen in human patients.
MitoPark mice are generated through crossing knock in
mice expressing Cre recombinase (driven by the dopamine
transporter promoter) with mice in which the Tfam gene is
flanked by loxP recombination sites, creating a model in
which Tfam is only absent from neurons that express the
dopamine transporter (Galter et al. 2010). When tested in an
open field environment, these animals show decreases in
horizontal(walking) andvertical(rearing) behaviors,startingat
approximately 24 weeks of age. Interestingly, these animals
also show decreases in dopamine, DOPAC and HVA levels in
thestriatumandanteriorcortex(asmeasuredbymicrodialysis),
corresponding with the behavioral data, and also mimicking
human patients (Galter et al. 2010). The bradykinesia seen in
these animals also responds well to treatment with the
dopamine precursor levodopa (L-DOPA) at a doses of 4 and
20 mg/kg (Galter et al. 2010), further underlying the validity
of this particular animal model for PD.
parkin, PINK1 and DJ-1 mice
parkin, PINK1 and DJ-1 are three knockout mouse models
for autosomal-recessive PD (for review, see Dawson et al.
2010). More than 100 mutations in parkin have been
reported in PD patients and account for 50% of familial
cases of PD; PINK1 mutations are recessively inherited.
Both parkin and PINK1 knockout mice do not exhibit any
abnormalities in dopamine levels or dopaminergic neurons,
nor do they show dysfunctions in locomotion. However,
both parkin and PINK1 mice show deficits in nigrostriatal
dopamine transmission and have mild mitochondrial
defects (Dawson et al. 2010).
DJ-1 is a member of the ThiJ/Pfpl family of molecular
chaperones; it is protective against oxidative stress in
mitochondria and plays a small role in early-onset PD
(Gasser 2009). DJ-1 knockout mice do not exhibit any
major behavioral abnormalities, and dopamine neuron
numbers and striatal dopamine levels remain normal.
However, neurotransmission in the nigrostriatal circuit and
mitochondrial dysfunction has been observed in some DJ-1
animals, similar to PINK1 and parkin knockouts (Andres-
Mateos et al. 2007). It seems therefore that these three
genetic animal models for PD may only represent symptoms
associated with the onset of the disease, and are not suitable
for studies examining the efficacy of treatments after
substantial neurodegeneration has occurred.
Rotenone, MPTP, 6-OHDA and lactacystin
induction models
Rotenone is a powerful mitochondrial complex I inhib-
itor, and has been used as an induction model for many
neurodegenerative diseases (Chou et al. 2010). Rotenone
easily passes through the blood brain barrier and cell
membrane, due to its lipophilic structure (Nehru et al.
2008). Once absorbed, it can cause the destruction of
dopamine neurons and results in PD-like symptoms and
behaviors (Alam et al. 2004). In the brain, this induction
model results in increased iron concentrations, which may
lead to hydroxyl radical formation. Rotenone also causes
decreases in the thiol antioxidant glutathione (GSH),
which is responsible for peroxide clearance from the
brain, and causes oxidative damage to lipids, proteins,
and DNA in the substantia nigra (Vali et al. 2007). This
pathology is similar to the post-mortem brains of PD
sufferers, and therefore is a popular model for PD
research in vivo.
The drug 1-methyl 4-phenyl 1,2,3,6-tetrahydropyridine
(MPTP) is also a complex I inhibitor, and works by
inhibiting oxidative phosphorylation of complex I, increasing
ROS production, and decreasing ATP (Patki et al. 2009).
MPTP may trigger neurodegeneration through the destruc-
tion of dopamine neurons in the SNpc, considered as one of
the defining characteristics of PD.
Administration of 6-hydroxydopamine (6-OHDA) also
results in the widespread deterioration of dopaminergic
J Inherit Metab Dis (2012) 35:193–210 199neurons in the nigrostriatal pathway, but does not result in
the generation of Lewy bodies or altered α-synuclein
expression, as seen in PD patients (Xiong et al. 2009).
The working mechanism of this neurotoxin is not exactly
known, but it is thought that administration of 6-OHDA
results in extracellular auto-oxidation and the induction of
oxidative stress from the resulting oxidative products
(Hanrott et al. 2006).
Exposure to the ubiquitin-proteasome (UPS) inhibitor
lactacystin results in a phenotype similar to that of PD
patients by causing noradrenaline, serotonin and dopamine
neurons to degenerate and Lewy body accumulations when
injected into the median forebrain bundle (Zhu et al. 2008).
However, none of these induction models result in the
complete spectrum of the characteristic chronic disease
symptomologies. Therefore, while induction models are
highly useful when examining neurological diseases, better
models are needed which encompass the entire scope of the
disease progression.
Models for Huntington’s disease
R6/1 and R6/2 knock-in and YAC transgenic mice
There are many particular types of mouse models for
Huntington’s disease, including mice that contain only a
fragment of exon-1 of the human huntingtin gene contain-
ing polyglutamine mutations (this in addition to both alleles
of murine wild-type huntingtin, Hdh), mice with pathogenic
CAG repeats inserted into existing CAG expansion in the
murine huntingtin Hdh (knock ins), and mice that express
the full-length human HD gene (including murine Hdh)
(Adhihetty and Beal 2008; Wang and Qin 2006). One such
strain, called R6/2, generated with approximately 155 CAG
repeats inserted into their huntingtin genes, show subtle
motor deficiencies and learning deficits one month after
birth, with symptoms becoming more pronounced at two
months, and becoming fatal at three to four months (Levine
et al. 2004). The brain pathology of these mice shows
nuclear inclusions present throughout the brain, and can be
detected as early as three weeks after birth. Importantly,
these inclusions have also been observed in the post
mortem brains of HD patients. Also, R6/2 mice show loss
of dendritic spines, as well as decreases in spine and
dendrite numbers, in the striatal and cortical somatoden-
dritic areas (Levine et al. 2004). This correlates with the
theory that early degeneration of the cortical-striatal
pathway can occur with the accumulation of huntingtin
protein in cortical neurons (Tang et al. 2007). MSSNs in
particular are more sensitive to N-methyl-D-aspartic acid
(NMDA), an amino acid derivative that mimics glutamate’s
working mechanism (and therefore has effects on MSSNs
susceptibility to excitotoxicity); NMDA-induced cellular
swelling is indeed increased in the R6/2 knock-in (Levine
et al. 1999). The R6/2 mouse has therefore become a
popular model for testing putative new treatments for HD.
These therapies include those that work on excitotox-
icity (remacemide, riluzole), mitochondrial functioning
(coenzyme Q, creatine), aggregate formation (Congo
red, trehalose) and transglutaminases and caspases such
as cystamine and minocycline, respectively (Levine et
al. 2004). Several of these treatments prolonged survival
and/or delayed the appearance of motor deficiencies in
the R6/2 mouse.
R6/1 mice, similar to R6/2, show the same symptomol-
ogy, but with a slower disease progression and milder
phenotype. Interestingly, studies with this knock-in show
that not only do these mice exhibit the traditional
symptomology of HD, but also co-morbid depressive
symptoms, as seen in the tail suspension and Porsolt forced
swim paradigms (Pang et al. 2009). These depressive
behaviors were ameliorated through cage enrichment,
wheel running, and treatment with the selective seroto-
nin reuptake inhibitor (SSRI), sertraline, but this study
also showed that there were marked differences between
male and female animals, stressing the importance of
gender selection when performing behavioral studies
(Pang et al. 2009).
Yeast artificial chromosome (YAC) mice were created
to specifically model the CAG repeating aspect of HD,
and may have 46, 72 or 128 CAG repeats. The
corresponding Huntington’s symptomology is similar to
patients with HD, in that animals with more repeats
show a more severe phenotype (Van Raamsdonk et al.
2007). YAC128 mice show atrophy in several brain
regions, including the striatum, hippocampus and cere-
bellum. These animals also develop severe cognitive
deficits, altered pre-pulse inhibition, and are at first
hyperactive in an open field environment, but later
become hypoactive. YAC 72 and 46 mice show similar
deficits, but to a lesser extent, and later in life, similar to
human HD patients (Van Raamsdonk et al. 2007).
3-NP induction model
The complex II and succinate dehydrogenase inhibitor 3-
nitropropionic acid (3-NP) is used as an induction model
for HD; after exposure, animals show motor dysfunctions
through degeneration of striatal neurons, similar to
patients suffering from HD (Duan et al. 2000). This
compound is thought to generate (indirect) excitotoxicity
through the stimulation of NMDA receptors in the
striatum, but this remains a matter of some controversy
(Kim et al. 2000).
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SOD1
G93A transgenic mice and rats
These two genetically manipulated rodent strains are not
only used for the study of ALS, but are also useful in vivo
models for HD and PD. Transgenic animals expressing
SOD1
G93A carry a mutated, mis-folded form of the human
gene for SOD1. Energy deprivation following the
impairment of the mitochondrial respiratory chain, alter-
ations in intracellular calcium handling and activation of
the apoptotic pathway results in the subsequent destruc-
tion of mitochondria in the spinal cord and the
degeneration of motor neurons and astrocytes in cortical
and spinal cord/brainstem areas (Israelson et al. 2010;
Reyes et al. 2010; Lenzken et al. 2011). This mutation
leads to gait abnormalities, as seen on the rotarod
paradigm, deficiencies in grip strength and a truncated
life span (Gurney et al. 1994; Lenzken et al. 2011).
TDP-43 transgenic mice
TDP-43, a DNA/RNA binding protein, played an unknown
role in the development of neurodegenerative diseases, such
as ALS, until recently. The role played by TDP-43 in ALS
pathology became largely significant when it was shown
that mutations in this gene resulted in ubiquinated protein
aggregates as seen in many cases of ALS. TDP-43 mice
show developmental retardation, motor deficits and prema-
ture death (Shan et al. 2010; Xu et al. 2010). Interestingly,
mice that were bred with higher numbers of transgene
copies showed a more severe phenotype. For example,
animals from the W1 line, with the highest number of
copies, were significantly smaller compared to non-
transgenic littermates, and died at three weeks of age.
Those animals from lines W2 and W3, with lower numbers
of transgene copies, showed a less severe phenotype and
survived to adulthood. However, male animals from these
two lines showed a significantly more severe phenotype
compared to female transgene littermates. Female TDP-43
mice showed no significant reductions in body weight and
developed tremors only at 3 months of age, further
underlying the importance of gender selection when
performing in vivo behavioral studies (Shan et al. 2010).
Models for Alzheimer’s disease
PS1/A246E, Tg2575 and 3xTG-AD transgenic mice
The PS1/A246E transgenic mouse is used as a model for
autosomal dominant, early onset Alzheimer’s disease, and
is often used to examine early neurochemical changes
associated with the disease (Strazielle et al. 2009).
Mutations in the presenilin 1 (PS1) gene lead to increased
production of the amyloidogenic form of Aβ peptide.
The neurotoxic properties of this increased Aβ peptide
m a yl e a dt oi n c r e a s e do x i d a t i v es t r e s sa n dt h e r e f o r e
increased mitochondrial damage (Wang et al. 2005). This
particular mouse model does not, however, show severe
cognitive impairments, and shows comparable cognition
performance compared to controls in the Morris water
maze (Janus et al. 2000).
The popular Tg2576 murine model of Alzheimer’s
disease, generated by over-expressing a mutated form of
human AβPP (K670M/N671L), is often used in studying
AD because it exhibits plaque formation in the brain and
progressive memory impairments, similar to those suffering
AD (Seo et al. 2010). More specifically, cognition testing in
these animals reveals that they show deficits in the Morris
water maze, the Y-maze and several kinds of passive
avoidance paradigms (King and Arendash 2002). Also,
unlike many of the animal models named previously, this
particular model is widely commercially available and
therefore easily obtainable for those wanting an in vivo
AD model. The AD-like pathology shown by these animals
is thought to be due to the transgenic expression of a
mutant form of human AβPP in the brain, which may also
have effects on neurons in the spinal cord, which may also
partially account for the motor dysfunctions seen in these
animals (Seo et al. 2010).
The triple mutant mouse 3xTG-AD expresses the mutant
genes APPswe, PS1M146Vand tauP301L, and exhibits not only
the cognitive deficits seen with AD, but also show the
characteristic extracellular senile plaques and neurofibrillary
tangles associated with the disease (Peng et al. 2010). These
mice also show decreases in vitamin E and glutathione
(two non-enzymatic antioxidants) levels, suggesting that
these animals are much more susceptible to oxidative
stress due to their decreased levels of endogenous
antioxidants (Resende et al. 2008).
Tau/Harlequin double mutant mice
These mice were generated by crossing the Harlequin
mouse, whose genetic makeup has been previously
discussed, with mice expressing human mutant tau tg
(P301L), a mouse model for human tau pathology seen
in AD. These mice express the longest isoforms of
human tau, together with the pathogenic mutation P301L,
am u t a t i o ni nt h eh u m a nMapt gene encoding tau protein
(Attems et al. 2011). The combination of these two strains
results in a mouse model that shows increases in tau
pathology, apoptotic neurodegeneration, and muscular/
motor deficits (Kulic et al. 2009). This model may be
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between mitochondrial dysfunction and AD, as it
incorporates the genetic makeup of the harlequin mouse
(including the AiF mutation), combining the neurode-
generative aspects of complex I dysfunction with the tau
pathology found in AD patients.
VDAC deficient mouse
Voltage-dependent anion channels (VDAC) are proteins
that form a voltage-gated ion channel in the mitochon-
drial outer membrane, allowing translocation of metab-
olites across the membrane (Graham et al. 2002).
Humans and mice have three isoforms (VDAC1, VDAC2
and VDAC3). Mouse mutants generated for the VDAC1,
VDAC 3 and VDAC 1/3 isoforms showed significant
deficits in learning and memory paradigms (Weeber et al.
2002;G r a h a me ta l .2002). When knockout mice for all
three of these isoforms were tested in the Morris water
maze, all three exhibited deficits in spatial learning, and
did not exhibit any motor control or nociceptive deficits
(Weeber et al. 2002). Electrophysiological examination of
these animals revealed decreased plasticity of hippocam-
pal neurons, further underlining the effects of VDAC
deficiency and subsequent mitochondrial respiratory
chain dysfunctions on cognition (Graham et al. 2002).
VDAC 1 knockout rats are also useful as a model for
inherited ALS; decreased VDAC activity caused by
mutated SOD1 causes expedited disease progression
and death at an earlier age than other ALS models
(Israelson et al. 2010).
Twinkle (or deletor) knockout mouse
Twinkle, a nuclear-encoded mitochondrial DNA (mtDNA)
helicase, may cause adult-onset progressive external
ophthalmoplegia (PEO) with multiple mtDNA deletions
(Tyynismaa et al. 2005) .T h eT w i n k l em o u s em o d e l
generated for these mutations shows the same symptomol-
ogy as PEO patients and show progressive deficiencies in
cytochrome c oxidase. However, these animals do not age
prematurely, and do not show deficiencies in motor
coordination. When these mice were tested in the rope
grip, rotarod and wheel running paradigms, they showed
no significant decreases in motor coordination, muscle
strength or gaiting (Tyynismaa et al. 2005). Therefore,
although these mice are a sufficient model for some
aspects of adult-onset mitochondrial disorders, such as
PEO, this particular model would be insufficient for
testing in paradigms assessing cognition and motor
function, as they showed no abnormalities in brain
function or pathology.
Behavioral modeling of mitochondrial dysfunction
When studying the effects of any pharmacological or
nutraceutical intervention on neurodegenerative and
psychiatric disorders, it becomes necessary to observe
the effects of that therapy on behavior. The above
named mouse and rat in vivo models offer a unique
opportunity to examine the effects of pharmaceutical
and nutraceutical interventions on behaviors such as
motor coordination, learning and memory, and nocicep-
tion, for example (Crawley 1999). When using mouse
models for mitochondrial dysfunction, it becomes par-
ticularly interesting to examine behaviors associated
with motor coordination and cognition, as these areas
of the brain may be the most affected by these
dysfunctions. However, one must exercise caution when
using animal models: the gender, age and genotype of the
animal can play a pivotal role in the experimental
outcome. For example, MPTP treatment results in
significantly higher levels of neurotoxicity in older
animals; younger animals seem better able to recover
functionality after MPTP-induced damage (Patki et al.
2009). It is therefore crucial, when using the MPTP
model of induction, to take the age of the experimental
animals into account.
Muscular coordination and motor function
The rotarod and rope grip paradigms are tests for motor
function and coordination, and are more commonly used
for examining behaviors related to movement disorders
(HD, PD, and ALS). The rotarod requires the animal to
walk on a rotating rod which is slowly increasing in
speed from 4 to approximately 40 rpm. The purpose of
this paradigm is to examine motor coordination, and the
gradual increase in rpm allows for animals that have no
handicaps in motor function to move comfortably. The
rope grip test, similar to the rotarod, requires the animal,
when placed on a rope, to grasp the rope with both fore-
a n dh i n dl i m b si no r d e rt os h i m m yt oo n ee n di no r d e r
to escape. Those animals with decreased motor function
and muscle strength will generally fall from the rotarod
and the rope earlier than those without. However, when
working with any genetically modified or induction
model, it is important to perform these simple tests to
rule out motor coordination dysfunctions before testing
in other paradigms. Defects in motor coordination may
lead to false negative results in other behavioral
paradigms involving movement and behavior, such as
cognition and anxiety tests, and should therefore be
examined as early as possible before further testing
takes place.
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Mitochondrial-induced neuronal death in such brain areas
as the hippocampus may result in cognitive deficits, as seen
in patients with AD (Dragicevic et al. 2010). There are
several paradigms that may be used to test cognition in
rodents. Among them are the Morris water maze, the
Y-maze, and the novel object recognition test. The Morris
water maze gives a comprehensive overview of hippocampal
memory, including spatial memory, long-term memory and
long-term spatial memory, as well as learning abilities in
general. During the extensive training phase, rodents are
placed in a heated pool of water (1–1.5 meters in diameter,
heated to about 24°C), separated into four quadrants,
containing a small (5–10 cm in diameter) platform in one of
the quadrants. The platform is usually hidden, but may
sometimes be marked with a small flag. Each training trial
consists of four swimming trials, in which the rodent is
released at four different points in the maze, once in each
quadrant. After the four trials, the animal is removed from the
water, and after an inter-trial interval of anywhere between 60
to 120 minutes, will undergo another training session. All
animals undergo two to four training sessions per day, usually
forfourconsecutivedays.Importantly,theplatformplacement
remains the same for each animal (i.e., for some animals, the
platformisalwaysinquadrant1,forothers,quadrant2,andso
forth); visual cues are placed around the maze to assist the
animal with orientation. The test, or probe trial, is performed
on the fifth day of testing; the platform is removed from the
maze, and the animal is allowed to search for 60 seconds.
Time spent in the correct quadrant, and crosses over the
platform location, give an indication of how well the
animal has learned the task and its memory of the
platform location. The probe test can also be done days
and even weeks after the training trials, which is known
as an extinction test, in order to observe the animals’
long-term memory. Animals with learning deficits will
spend equal amounts of time in all quadrants.
The Y-maze paradigm tests the working memory of
rodents, by either testing their spontaneous alternation or
spatial recognition. As the name implies, the maze itself is
in the shape of a “Y”, and it is possible to close one or two
of the maze arms. However, to test spatial working memory,
the spontaneous alternation test requires that all arms be
open. The animals are placed at the end of the designated
entry arm and allowed to explore for five minutes. The
amounts of alternations are recorded and a score is
calculated. Alternations are characterized as the following:
assuming the entry arm is called A, and the other two arms
are called B and C, the animal should alternate between the
arms in a consecutive A – B – A – Co rA– C – A – B
pattern. An arm entry is scored when the animal enters the
arm with all four paws. The percent alternation can then be
calculated as such: (number of alternations/ (total number of
arm visits – 2)) * 100. For example, if a mouse has a (total of
19completealternations/(27totalarmvisits–2))*100=76%
alternation rate; between 60% and 80% alternation is normal.
Testing for spatial recognition memory requires that one arm
of the Y-maze be blocked, and the animal allowed to explore
the other two open arms. After a 5 to 15 minute exploration
period, the animal is removed, and will be placed back in the
maze, with the blocked arm now open, after an inter-trial
period of 30 minutes to 24 hours. The time spent in the novel
arm, the latency to exploring the novel arm, and numbers of
entries into the novel arm give an indication of the animal’s
memory of the familiar, already explored territory and the
novel area. Animals with severe memory deficits will not
alternate and will spend equal amounts of time in the familiar
and novel arms.
Similar to the Y-maze paradigm, novel object exploration
can also be used to test an animal’s memory of familiar and
novel objects. In this paradigm, the animals are placed in an
open field arena containing two identical objects. After an
acclimation period of 5 to 15 minutes, the animals are
removed from the open field and placed back in their home
cage for an inter-trial interval of 30 minutes to 24 hours.
For the test trial, one of the familiar objects is removed and
replaced with an object that differs from the remaining
familiar object. The animal is then placed back in the open
field, and the time spent exploring the new object and the
time spent in the area around it is recorded. Again, animals
with memory deficits will not show any preference for the
novel or familiar object. However, a word of warning about
animal testing with novelty: rodents can also show
aversions to novel situations and objects, and while their
first instinct is usually to explore the unfamiliar, some
animals will show an aversion to novelty and avoid the new
object or environment altogether. It is therefore important to
take this possible confounder into account when using tests
focusing on novelty as a measure for memory.
Depression, anxiety and schizophrenia
The most popular models for depression are based on the
concept of “learned helplessness” in rodents. These
paradigms consist of a slightly noxious stimulus, such as
being suspended by the tail or placement in a beaker of
warm water, known respectively as the tail suspension and
forced swim (or Porsolt swim test) paradigms. These
paradigms both focus on the time spent by the animal in
struggling/attempting to escape the situation. When the
animal ceases to struggle, this is scored as “learned
helplessness”. Antidepressants have been found to be
efficacious in both these paradigms, as animals receiving
J Inherit Metab Dis (2012) 35:193–210 203drug treatment struggle/swim longer than those receiving
the vehicle.
Anxiety can best be observed in rodents using
paradigms designed to examine behaviors in a mildly
stressful environment, such as an open field or elevated
plus maze. Both of these paradigms are used to examine
anxiety behaviors in rodents; the elevated plus maze
consists of a + −shaped maze, usually half a meter above
the floor, containing two open and two closed arms.
Animals showing less anxiety behaviors will enter and
spend more time on the open (exposed) arm than those
with more stress. Similarly, the open field paradigm, which
consists of a large open arena, usually about 20 to 50 cm in
diameter, allows the observer to examine how often a rodent
will enter the center, more stressful, area of the open field, as
opposed to the less stressful periphery.
The best known paradigm for schizophrenia testing is
known as pre-pulse inhibition of startle. This paradigm, as
the name implies, examines the startle capabilities of the
test subjects in response to a loud auditory stimulus of
120 dB. Inhibition of startle behavior is achieved by a short
pre-pulse, milliseconds before the startle stimulus, of either
80, 82 or 85 dB. In normal rodents, the pre-pulse will
decrease the startle amplitude, but in models showing
schizophrenic behavior, no inhibition of startle is apparent.
Pharmaceutical and nutraceutical interventions
for mitochondrial disorders
The above named animal models and behavioral paradigms
can be used to explore the efficacy of known and novel
treatments for diseases resulting from mitochondrial dys-
function (Table 3). The following is a brief overview of the
most used pharmaceutical and nutraceutical interventions
for mitochondrial dysfunction-induced neurodegenerative
diseases and their effects on the previously mentioned
behaviors (for more comprehensive reviews, please see: Liu
et al. 2002; Navarro and Boveris 2008;F r i s a ra n d
Hroudova 2010).
Antidepressants
Mitochondrial dysfunction has long been known to be tied
to the development of several neurodegenerative diseases,
among which are PD, HD, AD and ALS (Lin and Beal
2006). These deficiencies have also been related to the
development of depression, anxiety, and schizophrenia
(Scaglia 2010). Along these lines, several forms of
antidepressants have been examined for their putative
effects on monoamine systems in the previously mentioned
diseases. Several kinds of dopamine agonists have been
examined in the treatment of PD, including pramipexole
and D-264, both dopamine D3 receptor agonists. Both of
these treatments have been shown to improve motor
performance on the rotarod and rope grip tests in the
MPTP induction model of PD (Li et al. 2010), and
interestingly, D-264 also increases brain-derived neurotrophic
factor (BDNF) levels in MPTP-treated mice, suggesting that
BDNF may also play a role in neuroprotection (Li et al. 2010;
Wu et al. 2010). At the mitochondrial level, these
compounds are thought to be neuroprotective, blocking
the effects of MPTP on mitochondrial complex I inhibition
and dopaminergic neuron loss (Li et al. 2010).
Similarly, the tricyclic antidepressant (TCA) nortriptyline
delayed disease onset and mortality in SOD1
G93A mice, and
rescued motor neurons in the spinal cord. The authors
hypothesize that treatment with this drug inhibited mito-
chondrial cytochrome c release and caspase activation in
the treated animals, protecting against ALS-associated
neurodegeneration. Treatment also delayed disease onset
in R6/2 knockout mice and delayed onset of rotarod-related
motor deficiencies, but accelerated disease progression
once symptoms began to manifest (Wang et al. 2007). The
authors suggest that this accelerated disease progression is
the result of accumulated toxicity of nortripyline after five
months of administration. These results suggest that
nortriptyline treatment, if administered early enough, may
be able to circumvent the development of ALS, perhaps as
well as other neurodegenerative diseases (Wang et al.
2007), but would not be a useful treatment for those
already suffering from such afflictions.
The mood stabilizer lithium has been shown to be
efficacious in the SOD1
G93A transgenic mouse model of
ALS; animals receiving daily doses of lithium had an
increased survival time of 36% (Fornai et al. 2008).
Treatment also delayed the onset of paralysis and limb
adduction, and improved performance in the rotarod and
grip strength paradigms (Fornai et al. 2008). Animals began
receiving treatment at day 75, when they were already
quite old, but not yet showing symptoms of the disease.
The authors hypothesize that treatment with lithium was
neuroprotective, in that it rescued spinal cord mitochon-
dria and produced significant decreases in α-synuclein,
ubiquitin, and SOD1 aggregates. To date, it is unclear
whether treatment with lithium after symptoms have
begun is efficacious in reversing damage to mitochondria
in motor neurons.
Serotonin receptor expression has been shown to be
decreased in the R6/1 mouse model for HD, and this mouse
also shows symptomology similar to those suffering from
depression and HD (Pang et al. 2009). Treatment with the
SSRI sertraline improved performance in the forced swim
depression paradigm: female knock-ins receiving sertraline
showed less immobility time compared to controls, but
there was no effect on male behavior. Interestingly, male
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J Inherit Metab Dis (2012) 35:193–210 205knock-ins showed improvements in the tail suspension
paradigm when treated with either sertraline or desipramine
(a TCA), but there was no effect of either drug on female
performance in the tail suspension paradigm. Further,
environmental enrichment also decreased depression-
related behaviors in the forced swim test in female knockouts,
but had no effect on males (Pang et al. 2009). However, the
working mechanisms of this SSRI on mitochondrial function
remain unknown; Kumar et al. (2011) theorize that treatment
with compounds like sertraline may protect against oxidative
damage and subsequent neuronal death from nitrogenous
free radicals.
Antioxidants
Since mitochondrial damage is highly attributed to oxida-
tive damage from ROS production (among others), the
examination of antioxidants in the battle against neurode-
generative and psychiatric disorders has become a topic of
much examination over the past years. In a study examining
the effects of lipoic acid (an organosulfur compound and
putative antioxidant found in almost all food, but in higher
concentrations in spinach, broccoli and liver) Packer et al.
(1997) found that treatment with this compound resulted in
improved motor performance and cognition in older mice
(20–23 months old), while there were no effects in younger
animals. Other experiments with lipoic acid have shown
that this antioxidant also increases locomotion as well as
improving memory in older rats (Liu et al. 2002), which
indicates that this particular compound may be efficacious in
the treatment of AD. These particular experiments have
many advantages, as they examined the effects of lipoic
acid in older mice without using any pharmacological
induction, a situation much more similar to that of
human patients.
Examinations of L-carnitine and its acetyl derivative,
acetyl L-carnitine (ALCAR), which both provide the acetyl
equivalents for the production of the neurotransmitter
acetylcholine, have shown that both of these antioxidants
result in improvements in age associated declines in
cognition and locomotion, making these nutraceuticals
suitable for further use in AD research (Liu et al. 2002).
However, ALCAR is more often used in experimentation,
as it is better absorbed and passes more easily through the
blood brain barrier than L-carnitine. ALCAR also protects
neurons from toxicity from those compounds functioning as
mitochondrial uncouplers or inhibitors (Virmani et al.
1995), and increases brain GABA levels (Liu et al. 2002).
Interestingly, this antioxidant seems to have better results at
lower doses; when given at concentrations of 0.15%,
0.2% and 0.5%, treatment resulted in decreases in
mitochondrial loss in the hippocampal dentate gyrus of
older animals (Liu et al. 2002). Treatment with this
compound at 1.5% did not have as drastic effects as the
lower doses, perhaps either due to a saturation effect or
perhaps this antioxidant becomes neurotoxic at higher
doses. Studies examining the combined effects of ALCAR
with lipoic acid show significant increases in improve-
ments on spatial memory, compared to treatment with
either antioxidant alone (Liu et al. 2002).
Oral administration of the antioxidant creatine (a
nitrogenous organic acid) resulted in motor performance
improvements, extended life span, and protected against
neuronal loss in the substantia nigra and motor cortex of
SOD1
G93A mice, indicating that this organic acid may be
useful in future studies examining the effects of creatine on
such movement disorders as PD and ALS. Treatment with
this compound also decreased the number of Huntington
positive aggregates in the brain, but was not efficacious in
alleviating deficits in cognition (Adhihetty and Beal 2008),
rendering this particular antioxidant less suitable for the
treatment for the cognitive deficits associated with AD.
Melatonin is an endogenous antioxidant manufactured by
the pinealgland and slows the process of neuronalsenescence
(Srinivasan et al. 2006). Four months’ administration of
melatonin to amyloid precursor protein (APP) transgenic
mice, an in vivo AD model, resulted in significant improve-
ments in cognition, learning and memory, and decreased Aβ
deposits in the frontal cortex (Cheng et al. 2006). The
authors also show that melatonin administration decreases
oxidative stress and neuronal apoptosis, perhaps through
increases in SOD activity and inhibition of lipid peroxidase
production (Cheng et al. 2006).
Centrophenoxine, an antioxidant and nootropic,
improves motor function on the rotarod and has positive
effects on DA levels after rotenone treatment, a popular
induction model of PD (Nehru et al. 2008). Studies with
this compound have also found that it can improve
cognitive performance in rats injected with the muscarinic
antagonist scopolamine, used to impair memory (Petkov et
al. 1988). Centrophenoxine is thought to work by stimulat-
ing glucose uptake and oxygen consumption and increasing
energy metabolism in the brain. However, this nootropic
has been little examined in other animal models for
neurodegenerative diseases, and may prove effective in
models for AD as well.
Other pharmaceutical and nutraceutical interventions
The monoamine oxidase-B (MAO-B) inhibitors rasagiline
and seleginine show promising results in C57Bl/6 mice
with a compromised ubiquitin-proteasome (UPS) system,
achieved through microinjection of the drug lactacystin, a
UPS inhibitor, in the median forebrain bundle (Zhu et al.
2008). The resulting phenotype is similar to that of PD
patients; pre-treatment with these two compounds not only
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protects dopamine neurons from lactacystin-induced damage
and increased the concentrations of dopamine and its
metabolites 3,4-dihydroxy-phenylacetic acid (DOPAC) and
homovanillic acid (HVA) (Zhu et al. 2008). However,
treatment after lactacystin-induced damage did not result in
such robust improvements: there were no significant effects
on rotarod performance, but some improvement in open field
motility (Zhu et al. 2008).
M30, an iron chelating compound derived partly from
rasagiline, decreases motor dysfunctions and prolongs the
lifespan of elderly SOD1
G93A mice (Kuperschmidt et al.
2009). The authors hypothesized that this compound
m a yw o r kb yr e g e n e r a t i n gm o t o rn e r v e s ,i n d u c i n g
neurodifferentiation and axon sprouting, all leading to
the re-innervation of muscle fibers. Interestingly, treat-
ment with M30 also raises BDNF levels, suggesting a
greater role for this neurotrophic factor than previously
believed. Many have hypothesized that BDNF plays a
major role in the development of depression (Krishnan
and Nestler 2010; Cryan and Slattery 2010), and
therefore may be a key component in many cases of
depression comorbidity seen in those with neurodegenerative
diseases, because neurodegeneration may result in decreased
BDNF levels, neuronal damage in the hippocampus, and
subsequent depression.
Pre-treatment with the non-metabolizable glucose ana-
logue 2 deoxyglucose (2DG), combined with dietary
restriction, reduced damage to dopamine neurons in the
substantia nigra and improved motor behaviors on the
rotarod in mice exposed to MPTP, an induction model for
PD (Duan and Mattson 1999). The authors theorize that
2DG works by reducing basal levels oxidative stress though
decreasing protein oxidation and that, combined with
dietary restriction, results in a “stress response” which
may have a beneficial effect on lifespan prolongation.
Previous studies have shown that caloric restriction can
indeed have beneficial effects on neurodegenerative diseases,
perhaps by influencing adult neurogenesis (Levenson and
Rich 2007). However, extensive research needs to be done
before this can be proven equivocally. This experiment does
not show the effects of either 2DG or dietary restriction on
animals already exposed to MPTP, and whether or not
dietary restriction and/or 2DG exposure would help to repair
damage already present in the brain.
Coenzyme Q10, a component of the electron transport
chain and a key constituent in cellular respiration, given in
conjunction with the NMDA receptor antagonist remaci-
mide, results in increased survival time in a transgenic
model for HD, R6/2 mice. Combined treatment was more
efficacious than treatment with either compound by itself;
mice treated with this combination showed significant
improvements in rotarod performance and less loss of body
weight compared to those groups treated with either
compound by itself (Ferrante et al. 2002). Further,
coenzyme Q10 has been shown to be neuroprotective in 3-
NP induction models (Yang et al. 2009). These results
further underline the point that treatment for mitochondrial
dysfunction diseases will not be straightforward; there will
not be one “cure-all” for the disease. Multiple combinations
of treatments may be necessary not only to combat the
symptoms of these diseases, but to cure them as well.
Treatment with the spice curcumin, an active polyphenol
isolated from turmeric (Curcuma longa), has been shown to
improve cognitive deficits in the Tg2576 AD mouse model
(Seo et al. 2010). Curcumin exposure not only rectified
gaiting deficiencies seen in the transgenic mice, it also
resulted in significant decreases in characteristic plaque
pathology and neuronal loss in the brain, similar to what is
seen in human AD patients (Seo et al. 2010). Others have
also shown that curcumin also improves performance in the
Morris water maze; mice receiving curcumin showed
shorter escape latency compared to vehicles (Kumar et al.
2011). Some hypothesize that this compound acts to reduce
oxidative damage, plaque build-up and levels of insoluble
amyloid, possibly through chelating iron and copper on
beta amyloid, and can improve cognition through the
stimulation of the cholinergic system (Pan et al. 2008).
Conclusions
The literature reviewed above gives a large overview of
previous studies performed with animal models of mito-
chondrial dysfunction, and the effects of pharma- and
nutraceutical interventions on behavior. However, it is of
note that almost all of these studies focus on the neuro-
protective qualities of the given compound. There is little
data on the power of these treatments to cure or at least treat
symptoms once they have begun to manifest. While
neuroprotection is an important aspect of preventing
neurodegenerative and CNS afflictions, it is not reasonable
to suggest that the population at large begin chronic
treatment with antidepressants, for example. The ideal
solution would be to eliminate the disease through gene
therapy, removing the cause of the disease at its source,
before symptoms even begin. However, this is assuming
that all diseases have a genetic basis, which may not be
entirely true. It is of note that for some models of
mitochondrial dysfunction, there is no need for genetic
manipulation or pharmacological induction. Studies done
by Gong et al. (2010) have shown that chronic stress may
result in damages to mitochondrial ultrastructure and
function in the brain. It has already been hypothesized by
many that dysfunctions in the hypothalamus-pituitary-
adrenal gland (HPA) axis, due to increased levels of stress
J Inherit Metab Dis (2012) 35:193–210 207hormones, may also result in stress and depression, both of
which have been linked to mitochondrial dysfunctions
(Braw et al. 2006; Garcia et al. 2011; Clay et al. 2010). It
may therefore be so that, in conjunction with genetic
modificationandinductionmodels,environmentalmodelslike
thoseofchronicstresscouldalsobeusedtostudytheeffectsof
mitochondrial dysfunctions on brain disorders. The causes of
some diseases are as of yet still unknown, but factors such as
environment and diet may also play key roles in disease
development. We need to be able to find the source of these
dysfunctions and prevent them from leading to the aforemen-
tioned maladies, and herein lays our greatest challenge.
The glut of studies done examining mitochondrial
dysfunction diseases shows us that there is still much to
be learned about the nature of these illnesses, their causes,
and their cures. With the help of animal models, pharma-
ceutical and nutraceutical interventions, we can perhaps
make further progress into (and hopefully out of) the mire.
However, it is imperative to remember that the answer to
this riddle may be complicated; it may be that no one
treatment will be the “magic bullet”; the answer may lie in
a combination of nutra- and pharmaceuticals, perhaps in
conjunction with external environmental influences, such as
dietary restriction. While current animal models are
certainly imperfect and may not necessarily mirror all the
symptoms and pathology of human patients, they are
invaluable for examining specific aspects of mitochondrial
dysfunctions, and should be recognized for the advantages
they offer to the study of neurodegenerative diseases.
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